Arrowhead Pharmaceuticals (NASDAQ:ARWR) Research Coverage Started at UBS Group

UBS Group started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $109.00 target price on the biotechnology company’s stock.

A number of other brokerages have also issued reports on ARWR. Piper Sandler restated an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. JPMorgan Chase & Co. lifted their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Leerink Partners boosted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research note on Wednesday, June 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Finally, Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Stock Down 4.4%

NASDAQ:ARWR opened at $55.90 on Thursday. The company has a market cap of $7.87 billion, a PE ratio of -24.84 and a beta of 1.29. Arrowhead Pharmaceuticals has a twelve month low of $36.57 and a twelve month high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The company’s 50 day moving average is $75.53 and its two-hundred day moving average is $75.86.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. During the same period in the prior year, the business posted ($1.26) EPS. The company’s quarterly revenue was up 171.0% on a year-over-year basis. Analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. Optiver Holding B.V. raised its stake in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares during the last quarter. Versant Capital Management Inc raised its position in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC raised its position in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in Arrowhead Pharmaceuticals during the second quarter valued at approximately $39,000. Finally, First Horizon Corp lifted its holdings in Arrowhead Pharmaceuticals by 36.2% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 174 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported interim Phase 1/2a results for ARO-MAPT, its investigational Alzheimer’s treatment. The drug reportedly crossed the blood-brain barrier and produced up to a 73% reduction in tau, a protein associated with Alzheimer’s disease. The results support the potential of Arrowhead’s TRiM platform for delivering RNA therapies into the central nervous system. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: UBS initiated coverage of ARWR with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reiterated Buy ratings with targets of $115 and $120, respectively. The targets reflect analysts’ confidence in Arrowhead’s pipeline and potential long-term upside. Arrowhead Pharmaceuticals Receives a New Rating from UBS
• Positive Sentiment: HC Wainwright projects Arrowhead could earn $9.61 per share in fiscal 2031, a sharp contrast with the expected loss of $3.62 per share for the current fiscal year. This highlights the firm’s view that commercialization of Arrowhead’s pipeline could significantly improve future profitability.
• Neutral Sentiment: The ARO-MAPT findings are interim, early-stage results and will require confirmation in larger, later-stage trials before they can support regulatory approval or commercial revenue.
• Negative Sentiment: After the initial data-driven surge, investors may be taking profits and reassessing valuation. Arrowhead remains unprofitable, recently missed quarterly EPS expectations, and faces substantial clinical, regulatory, and execution risks.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.